Yamazaki Haruhiko, Shimizu Satoru, Iwasaki Hiroyuki, Yoshida Tatsuya, Suganuma Nobuyasu, Yamanaka Takashi, Kojima Izumi, Masudo Katsuhiko, Toda Soji, Nakayama Hirotaka, Masuda Munetaka
Dept. of Breast and Endocrine Surgery, Kanagawa Cancer Center.
Gan To Kagaku Ryoho. 2017 Aug;44(8):695-697.
The 208 trial showed that lenvatinib has a significant antitumor effect on unresectable anaplastic thyroid cancer(ATC). Herein, we present a retrospective review of data from 7 patients with unresectable ATC who received lenvatinib in our hospital between May 2015 and October 2016. Two patients were men and 5 were women. The median age was 78(range, 72-85)years, and 1 patient had Stage IV A disease, 1 had Stage IV B, and 5 had Stage IV C at diagnosis, respectively. Three patients experienced a partial response and 1 patient experienced stable disease. The response rate was 43%, and the disease control rate was 57%. The median progression-free survival(PFS)was 4.1(range, 1.1-12.2)months. Grade 3 and Grade 4 gastrointestinal hemorrhage were observed in 2patients and Grade 3 anorexia was observed in 1 patient. Further clinical research seems to be needed to establish a treatment strategy involving lenvatinib for ATC.
208试验表明，乐伐替尼对不可切除的间变性甲状腺癌（ATC）具有显著的抗肿瘤作用。在此，我们对2015年5月至2016年10月期间在我院接受乐伐替尼治疗的7例不可切除ATC患者的数据进行回顾性分析。其中男性2例，女性5例。中位年龄为78岁（范围72 - 85岁），诊断时1例为IV A期疾病，1例为IV B期，5例为IV C期。3例患者出现部分缓解，1例患者病情稳定。缓解率为43%，疾病控制率为57%。中位无进展生存期（PFS）为4.1个月（范围1.1 - 12.2个月）。2例患者出现3级和4级胃肠道出血，1例患者出现3级厌食。似乎需要进一步的临床研究来确立涉及乐伐替尼治疗ATC的策略。
